Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force

被引：45

作者：

Kalra, Sanjay ^{[1
]}

Das, Ashok Kumar ^{[2
]}

Sahay, Rakesh Kumar ^{[3
]}

Baruah, Manash Pratim ^{[4
]}

Tiwaskar, Mangesh ^{[5
]}

Das, Sambit ^{[6
]}

Chatterjee, Sudip ^{[7
]}

Saboo, Banshi ^{[8
]}

Bantwal, Ganapathi ^{[9
]}

Bhattacharya, Saptarshi ^{[10
]}

Priya, Gagan ^{[11
]}

Chawla, Manoj ^{[12
]}

Brar, Kiraninder ^{[13
]}

Raza, Syed Abbas ^{[14
,15
]}

Aamir, Azizul Hasan ^{[16
]}

Shrestha, Dina ^{[17
]}

Somasundaram, Noel ^{[18
]}

Katulanda, Prasad ^{[19
]}

Afsana, Faria ^{[20
]}

Selim, Shahjada ^{[21
]}

Naseri, Mohammad Wali ^{[22
]}

Latheef, Ali ^{[23
]}

Sumanatilleke, Manilka ^{[18
]}

机构：

[1] Bharti Hosp, Karnal, Haryana, India

[2] Pondicherry Inst Med Sci, Pondicherry, India

[3] Osmania Med Coll & Hosp, Hyderabad, Telangana, India

[4] Excelcare Hosp, Gauhati, India

[5] Karuna Hosp, Mumbai, Maharashtra, India

[6] Hi Tech Med Coll & Hosp, Bhubaneswar, India

[7] Pk Clin, Kolkata, India

[8] Dia Care, Ahmadabad, Gujarat, India

[9] St Johns Med Coll, Bangalore, Karnataka, India

[10] Max Super Special Hosp, Delhi, India

[11] Fortis Hosp, Mohali, India

[12] BSES MG Hosp, Mumbai, Maharashtra, India

[13] Army Res & Referral Hosp, Delhi, India

[14] Shaukat Khanum Mem Canc Hosp & Res Ctr, Lahore, Pakistan

[15] Natl Def Hosp, Lahore, Pakistan

[16] Hayatabad Med Complex, Peshawar, Pakistan

[17] Norv Int Hosp, Kathmandu, Nepal

[18] Natl Hosp Sri Lanka, Colombo, Sri Lanka

[19] Univ Colombo, Colombo, Sri Lanka

[20] BIRDEM, Dhaka, Bangladesh

[21] Bangabandhu Sheikh Mujib Med Univ, Dhaka, Bangladesh

[22] Kabul Univ Med Sci, Kabul, Afghanistan

[23] Indra Gandhi Hosp, Dept Med, Male, Maldives

来源：

DIABETES THERAPY | 2019年 / 10卷 / 05期

关键词：

Calorie restriction mimetics; Calorie restriction facilitators; Consensus; GLP-1; RA; Incretin-based therapies; Type 2 diabetes mellitus; GLUCAGON-LIKE PEPTIDE-1; ONCE-WEEKLY DULAGLUTIDE; FATTY LIVER-DISEASE; FIXED-RATIO COMBINATION; GASTROINTESTINAL ADVERSE EVENTS; RECEPTOR AGONIST DULAGLUTIDE; RANDOMIZED CONTROLLED-TRIAL; INCRETIN-BASED THERAPIES; SYSTOLIC BLOOD-PRESSURE; OPEN-LABEL;

D O I：

10.1007/s13300-019-0669-4

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The advent of incretin mimetics such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has enriched the armamentarium for diabetes management owing to their glycaemic as well as extra-glycaemic benefits. The approval status and availability of this class of drugs vary widely across the globe. Being a relatively newer class of drug with numerous benefits, several national and international guidelines are working towards addressing clinical questions pertaining to the optimal use of GLP-1 RAs for the management of diabetes. Although the newer class of drugs are associated with significant benefits such as patient-centric approach, these drugs demand the providers to be vigilant and knowledgeable about the medication. The South Asian population is at higher risk of type 2 diabetes mellitus (T2DM) because of their genetic predisposition and lifestyle changes. Hence, prevention and management of T2DM and its associated complications in this population are of paramount importance. The current report aims to present an overview of current knowledge on GLP-1 RAs based on pragmatic review of the available clinical evidence. In addition, this report is a consensus of expert endocrinologists representing South Asian countries including India, Pakistan, Bangladesh, Nepal, Sri Lanka, Afghanistan and the Maldives on essential recommendations related to the use of GLP-1 RAs in a real-world scenario.

引用

页码：1645 / 1717

页数：73

共 238 条

[1]

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial [J].